← Leaderboards
Aparna C Ranganathan
State University Of New York At Albany
$385,232
Attributed
$385,232
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $120.8K · FY2005–11$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$385,232 · 2
By mechanism
R03$234,460 · 1
F32$150,772 · 1
Top collaborators
No co-investigators on record.
Most similar at State University Of New York At Albany
Same institution · by research overlap
- Julio A Aguirre-Ghiso$13,832,843
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsPathway InteractionsGrowthMalignant Epithelial CellMediatingNeoplastic CellCellsEndoplasmic ReticulumIn VitroLinkMapk14 GeneBehaviorMolecular ChaperonesNeoplasm MetastasisBiological Adaptation To StressCell LineCell SurvivalChemotherapyHypoxiaIntegrinsIn VivoIn Vivo ModelApoptosisPharmaceutical Preparations
Grant awards (7)
IDENTIFYING NOVEL MECHANISMS OF THERAPY RESISTANCE IN HNSCC$113,625
R03 · FY2011 · DE · contact PI
IDENTIFYING NOVEL MECHANISMS OF THERAPY RESISTANCE IN HNSCC$67,890
R03 · FY2010 · DE · contact PI
IDENTIFYING NOVEL MECHANISMS OF THERAPY RESISTANCE IN HNSCC$52,945
R03 · FY2010 · DE · contact PI
Mechanisms of cancer dormancy and drug resistance$38,788
F32 · FY2007 · CA · contact PI
Mechanisms of cancer dormancy and drug resistance$13,260
F32 · FY2007 · CA · contact PI
Mechanisms of cancer dormancy and drug resistance$50,428
F32 · FY2006 · CA · contact PI
Mechanisms of cancer dormancy and drug resistance$48,296
F32 · FY2005 · CA